TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3057810

Group type: EXPERIMENTAL
Intervention: Genotropin (recombinant somatropin) with 6-7 injections/week
Number of subjects: 194

Group type: COMPARATOR
Intervention: Genotropin (recombinant somatropin) with 2-3 injections/week
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Genotropin (recombinant somatropin)
Number of subjects: 194
Study: 28782380

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic interval training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 28196011

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (20 min, 1 mA)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (20 min, 1 mA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 25
Study: 25155998

Group type: EXPERIMENTAL
Intervention: Physician-pharmacist collaborative interventions
Number of subjects: 496

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 496
Study: 22253268

Group type: EXPERIMENTAL
Intervention: Dextrose 5% in Ringer lactate solution
Number of subjects: 62

Group type: COMPARATOR
Intervention: Ringer lactate solution (control)
Number of subjects: 62
Study: 21897343

Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with local anesthetic, lidocaine 0.5%, 10 mL
Number of subjects: 120

Group type: COMPARATOR
Intervention: Caudal epidural injections with 0.5% lidocaine, 9 mL, mixed with 1 mL of steroid
Number of subjects: 120
Study: 18420558

Group type: EXPERIMENTAL
Intervention: Randomized responding technique (RRT) treatment group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Refused participation group (prerelease interview)
Number of subjects: 0
Study: 17763204

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation (average cost of EURO5400)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation
Number of subjects: 195
Study: 15157792

Group type: EXPERIMENTAL
Intervention: 20 microg ethinylestradiol/150 microg desogestrel
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 20 microg ethinylestradiol/75 microg gestodene
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 30 microg ethinylestradiol/150 microg desogestrel
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 30 microg ethinylestradiol/75 microg gestodene
Number of subjects: 53
Study: 11491415

Group type: EXPERIMENTAL
Intervention: Indinavir
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Saquinavir
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Amprenavir
Number of subjects: 82
Study: 9760011

Group type: EXPERIMENTAL
Intervention: 20 microg desmopressin (dDAVP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Reference preparation
Number of subjects: 16
Study: 9316691

Group type: EXPERIMENTAL
Intervention: Nimodipine (120 mg/day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 3219881

Group type: EXPERIMENTAL
Intervention: 6 mg piretanide
Number of subjects: 24

Group type: COMPARATOR
Intervention: 40 mg furosemide
Number of subjects: 24
Study: 29607323

Group type: EXPERIMENTAL
Intervention: Low intensity cycling (LC)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moderate intensity cycling (MC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standing
Number of subjects: 36
Study: 27629371

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical management (MISM)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conservative management (CM)
Number of subjects: 101
Study: 25536706

Group type: EXPERIMENTAL
Intervention: Lyophilized powder of EPO alpha
Number of subjects: 40

Group type: COMPARATOR
Intervention: Liquid form of EPO alpha
Number of subjects: 40
Study: 22732136

Group type: EXPERIMENTAL
Intervention: Endoscopic DCR with silicone tubing (stent)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Endoscopic DCR without silicone tubing (no stent)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Overall success rate
Number of subjects: 173

Group type: COMPARATOR
Intervention: Comparison of failure rates
Number of subjects: 173
Study: 20022777

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with agalsidase alfa or agalsidase beta in Cohort 1B
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) prior to October 2006 in Cohort 1A
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Natural history of disease complications in Cohort 1C (no ERT)
Number of subjects: 244
Study: 18710324

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine (PPV) followed by protein‐conjugate pneumococcal vaccine (PCV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protein‐conjugate pneumococcal vaccine (PCV) followed by pneumococcal polysaccharide vaccine (PPV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine (PPV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Protein‐conjugate pneumococcal vaccine (PCV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine (PPV) as a booster after PCV
Number of subjects: 0
Study: 15695301

Group type: EXPERIMENTAL
Intervention: Active treatment (thalassotherapy, supervised exercise, and group education)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control treatment (treatment as usual)
Number of subjects: 58
Study: 12112158

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Antidepressant medication alone (Control)
Number of subjects: 50
Study: 10430767

Group type: EXPERIMENTAL
Intervention: Total circulatory arrest (CA)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Low-flow cardiopulmonary bypass
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Seizures in the perioperative period
Number of subjects: 158
Study: 7555553

Group type: EXPERIMENTAL
Intervention: Infant formula without intact cow's-milk protein
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 83
Study: 2210464

Group type: COMPARATOR
Intervention: Cimetidine 800 mg daily for 12 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg daily for 12 weeks plus cefixime 100 mg daily for the last two weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cimetidine only (H pylori positive)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cimetidine plus cefixime (H pylori suppressed)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups (at 24 weeks)
Number of subjects: 43
Study: 476225

Group type: EXPERIMENTAL
Intervention: MAO scale for women in group A
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: MAO scale for men in group A
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: MAO scales applied to another population
Number of subjects: 66
Study: 31296884

Group type: EXPERIMENTAL
Intervention: Nitisinone 1 mg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nitisinone 2 mg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nitisinone 4 mg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nitisinone 8 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 40
Study: 28187213

Group type: EXPERIMENTAL
Intervention: Airtraq®
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: McGrath®
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Macintosh
Number of subjects: 20

Group type: COMPARATOR
Intervention: Airtraq® vs McGrath®
Number of subjects: 20

Group type: COMPARATOR
Intervention: Airtraq® vs Macintosh
Number of subjects: 20

Group type: COMPARATOR
Intervention: All devices
Number of subjects: 20
Study: 25862600

Group type: EXPERIMENTAL
Intervention: sotDCS (0.75 Hz; 0-250 μV, 30 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 12
Study: 24112746

Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol solution (initial dose 20μg/hour, increased by 20μg/hour every 6 hours up to 80μg/hour for a maximum of 48 doses)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vaginal misoprostol tablets (25μg every 6 hours for a maximum of 8 doses)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol solution
Number of subjects: 200
Study: 21900191

Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa (30 U/kg body weight/infusion)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa (60 U/kg body weight/infusion)
Number of subjects: 29
Study: 19638025

Group type: EXPERIMENTAL
Intervention: Dual-task conditions (oral counting task)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Dual-task conditions (auditory-verbal reaction task)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Dual-task conditions (auditory-memory task)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Dual-task conditions (auditory-choice reaction task)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Dual-task conditions (articulation alone)
Number of subjects: 39
Study: 17717929

Group type: EXPERIMENTAL
Intervention: Modified Xiaoyao Pill combining amitriptyline (MXP-At)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Fluoxetine (control group)
Number of subjects: 64
Study: 15190050

Group type: EXPERIMENTAL
Intervention: American ginseng
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vietnamese ginseng
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Asian ginseng
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: American-wild ginseng
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Siberian ginseng
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11587992

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (3 months)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Symptoms for PE
Number of subjects: 400

Group type: COMPARATOR
Intervention: Nondiagnostic lung scan
Number of subjects: 400
Study: 9519224

Group type: EXPERIMENTAL
Intervention: Budesonide 4 mg nebulized suspension
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Budesonide 1 mg nebulized suspension
Number of subjects: 26

Group type: COMPARATOR
Intervention: Budesonide 0.8 mg pMDI with spacer
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Plasma budesonide levels
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Plasma cortisol levels
Number of subjects: 26
Study: 7865997

Group type: EXPERIMENTAL
Intervention: Bushen Migu Ye (BSMGY)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (Rhizoma Dioscoreae decoction)
Number of subjects: 43
Study: 2511532

Group type: EXPERIMENTAL
Intervention: Depot gonadotropin-releasing hormone analogue (leuprolide) given monthly for 24 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 887103

Group type: EXPERIMENTAL
Intervention: Oral choline administration for two weeks
Number of subjects: 20
Study: 30093401

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (2.5-10 mg/m2) administered in 1-4 cycles as a single agent (47%), combined with cytarabine (47%), or others (6%)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Number of subjects: 76
Study: 28476923

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation (70ml, 6.4 mmol nitrate)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PL) (0.0055 mmol nitrate)
Number of subjects: 14
Study: 25796535

Group type: EXPERIMENTAL
Intervention: Wii Balance Board anteroposterior sway velocity
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Wii Balance Board mediolateral sway velocity
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Wii Balance Board anteroposterior sway velocity adjusted with body mass index and Timed-Up-and-Go
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Wii Balance Board sway velocities
Number of subjects: 73
Study: 24374539

Group type: EXPERIMENTAL
Intervention: Patients with any complication (215 patients)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Patients without complications (399 patients)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Patients with any of 5 common complications (wound, chest, anastomotic leak, hemorrhage, cardiac event)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Patients without any of the 5 common complications
Number of subjects: 614
Study: 21901499

Group type: EXPERIMENTAL
Intervention: UC plus website (E-info gene(ca))
Number of subjects: 190

Group type: COMPARATOR
Intervention: UC (usual care)
Number of subjects: 190
Study: 19737502

Group type: EXPERIMENTAL
Intervention: Handheld Assisted Network Diary (HAND) assessment
Number of subjects: 168

Group type: COMPARATOR
Intervention: Paper-and-pencil Daily Social Diary (DSD)
Number of subjects: 168
Study: 17714104

Group type: EXPERIMENTAL
Intervention: 15 milliTESLA (mT) treatment using a prototype electromagnetic field device
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 40
Study: 15113951

Group type: EXPERIMENTAL
Intervention: Exclusive breast-feeding to 6 months (EBF)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Iron-fortified complementary foods (SF) from 4 to 6 months while continuing to breast-feed
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Medicinal iron supplements
Number of subjects: 119
Study: 11677866

Group type: EXPERIMENTAL
Intervention: Bisoprolol treatment
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Bisoprolol therapy
Number of subjects: 231
Study: 9439541

Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE) infusion (25 ng/kg/min)
Number of subjects: 8
Study: 7886779

Group type: EXPERIMENTAL
Intervention: Aminosidine, 14 mg/kg/d (max. 1 g daily) for 20 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sodium stibogluconate, 20 mg/kg/d for 20 days
Number of subjects: 34
Study: 2979254

Group type: EXPERIMENTAL
Intervention: Enprostil 8.75, 17.5, 35 and 70 micrograms
Number of subjects: 9

Group type: COMPARATOR
Intervention: Indomethacin 25 mg
Number of subjects: 9
Study: 30486262

Group type: EXPERIMENTAL
Intervention: Supervised group exercise (n = 18)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Individualized home‐based exercise (n = 18)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 54
Study: 28219920

Group type: COMPARATOR
Intervention: No CAD (SS=0)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Low SS (SS between 1 and 22)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Intermediate SS (SS between 23 and 32)
Number of subjects: 377

Group type: COMPARATOR
Intervention: High SS (SS ≥33)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Residual SS ≥8
Number of subjects: 377

Group type: COMPARATOR
Intervention: Low CABG SS
Number of subjects: 377

Group type: COMPARATOR
Intervention: High CABG SS
Number of subjects: 377
Study: 26163093

Group type: EXPERIMENTAL
Intervention: Protracted palliative radiotherapy (RT) course: 39Gy in 13 fractions (arm A)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CHT) followed by short-course palliative RT: 2-3 platinum-based CHT cycles followed by 10Gy in a single fraction or 16Gy in 2 fractions (arm B)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Both arms (A and B)
Number of subjects: 65
Study: 23066808

Group type: EXPERIMENTAL
Intervention: Cognitive speed of processing training (SOPT), a nonverbal, computerized intervention involving perceptual practice of visual tasks
Number of subjects: 126

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 126
Study: 21290963

Group type: EXPERIMENTAL
Intervention: 6-month self-efficacy-based, individually delivered, lower-extremity exercise and fitness walking intervention
Number of subjects: 26
Study: 19193343

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 4890

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 4890

Group type: EXPERIMENTAL
Intervention: Recurrent episode patients
Number of subjects: 4890

Group type: EXPERIMENTAL
Intervention: Single episode patients
Number of subjects: 4890
Study: 16608044

Group type: EXPERIMENTAL
Intervention: Jejunal pouch interposition (JPI)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Jejunal interposition (JI)
Number of subjects: 9
Study: 14735685

Group type: EXPERIMENTAL
Intervention: Temozolomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dacarbazine (DTIC)
Number of subjects: 0
Study: 15126606

Group type: EXPERIMENTAL
Intervention: Pre-diagnostic plasma selenium levels (5th versus 1st quintile)
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: Pre-diagnostic plasma selenium levels (5th versus 1st quintile) among men diagnosed after 1990
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: Pre-diagnostic plasma selenium levels (5th versus 1st quintile) among case subjects with elevated baseline PSA levels (PSA >4 ng/mL)
Number of subjects: 1163
Study: 10491060

Group type: EXPERIMENTAL
Intervention: 8-15 mmHg gradient compression hosiery
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 15-20 mmHg gradient compression hosiery
Number of subjects: 19

Group type: COMPARATOR
Intervention: No compression
Number of subjects: 19
Study: 7572650

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg once daily
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg 4 times daily
Number of subjects: 28
Study: 1690482

Group type: EXPERIMENTAL
Intervention: Prazosin (0.5 mg and then 1 mg twice daily for 4 days each and 2 mg twice daily for the remainder of the trial)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 376211

Group type: EXPERIMENTAL
Intervention: Trazodone (50 mg) 3 times a day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Imipramine (25 mg) 3 times a day
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31287130

Group type: EXPERIMENTAL
Intervention: Baska mask
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 150

Group type: COMPARATOR
Intervention: cLMA
Number of subjects: 150
Study: 26910406

Group type: EXPERIMENTAL
Intervention: Multidisciplinary Intervention (MI)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Brief Intervention (BI)
Number of subjects: 284
Study: 25983123

Group type: EXPERIMENTAL
Intervention: SRI = 100% (complete revascularization)
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: SRI between 50% to <100%
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: SRI <50%
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: SRI cutoff <70%
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Mean bSS
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Mean ΔSS after PCI
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Mean residual SYNTAX score
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Mean SRI
Number of subjects: 888
Study: 24302192

Group type: EXPERIMENTAL
Intervention: Folic acid and inositol
Number of subjects: 149

Group type: COMPARATOR
Intervention: Folic acid alone
Number of subjects: 149
Study: 21229373

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 240

Group type: COMPARATOR
Intervention: Leflunomide
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 240
Study: 19528337

Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 263

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 263
Study: 17169471

Group type: EXPERIMENTAL
Intervention: 7-month-olds processing of happy faces
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 12-month-olds processing of angry faces
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Visual preference assessment in infants
Number of subjects: 2
Study: 15521372

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 11709743

Group type: EXPERIMENTAL
Intervention: Trisequens(R) for 28 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sisare(R) for 21 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Trisequens(R)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sisare(R)
Number of subjects: 50
Study: 9143747

Group type: EXPERIMENTAL
Intervention: CHO-E beverage
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Caloric intake
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo or water
Number of subjects: 27
Study: 7910886

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg followed by 250 mg daily for 7 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no azithromycin)
Number of subjects: 19
Study: 29241762

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 26840330

Group type: EXPERIMENTAL
Intervention: Guanidinoacetic Acid (GAA) 2.4 grams per day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 21
Study: 26674497

Group type: EXPERIMENTAL
Intervention: Standard therapy (oxycodone and pregabalin) plus magnesium oxide
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard therapy (oxycodone and pregabalin) plus placebo
Number of subjects: 150
Study: 22930240

Group type: EXPERIMENTAL
Intervention: PTH(1-84) treatment over 24 months
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: PTH(1-84) treatment with ≥80% adherence
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: PTH(1-84) treatment
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Post-discontinuation of PTH(1-84) treatment
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Adherent group vs poorly adherent group
Number of subjects: 781
Study: 20854662

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg s.c. biweekly)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study: 19016147

Group type: EXPERIMENTAL
Intervention: Revascularization and stenting (group 1)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Medical treatment only (group 2)
Number of subjects: 82
Study: 16621200

Group type: EXPERIMENTAL
Intervention: M. vaccae-derived protein (PVAC) 50 microg
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: M. vaccae-derived protein (PVAC) 15 microg
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: M. vaccae-derived protein (PVAC)
Number of subjects: 165